Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The gross margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
0.00%
GROSS MARGIN AVG TTM
0.00%
GROSS MARGIN AVG 3Y
0.00%
GROSS MARGIN AVG 5Y
0.00%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Quince Therapeutics, Inc.
Market Cap
$7.55M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$7.76M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$7.25M
Gross Margin
14.92%
TTM Avg
28.44%
3Y Avg
28.69%
5Y Avg
27.44%
Market Cap
$7.95M
Gross Margin
0.00%
TTM Avg
-261.58%
3Y Avg
-106.09%
5Y Avg
-70.73%
Market Cap
$7.94M
Gross Margin
100.00%
TTM Avg
97.34%
3Y Avg
98.67%
5Y Avg
99.12%
Market Cap
$7.95M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$7.13M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
4.26%
5Y Avg
4.26%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | $7.55M | 0.00% | 0.00% | 0.00% | 0.00% |
| Skye Bioscience, Inc. (SKYE)vs › | $7.53M | 0.00% | 0.00% | 0.00% | 0.00% |
| ENDRA Life Sciences Inc. (NDRA)vs › | $7.76M | 0.00% | 0.00% | 0.00% | 0.00% |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.25M | 14.92% | 28.44% | 28.69% | 27.44% |
| Longeveron Inc. (LGVN)vs › | $7.22M | 69.76% | 72.87% | 54.39% | 49.20% |
| Aprea Therapeutics, Inc. (APRE)vs › | $7.95M | 0.00% | -261.58% | -106.09% | -70.73% |
| Traws Pharma, Inc. (TRAW)vs › | $7.94M | 100.00% | 97.34% | 98.67% | 99.12% |
| CNS Pharmaceuticals, Inc. (CNSP)vs › | $7.95M | 0.00% | 0.00% | 0.00% | 0.00% |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.13M | 0.00% | 0.00% | 4.26% | 4.26% |
| NeuroSense Therapeutics Ltd. (NRSN)vs › | $7.08M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
0.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
